Pharmacoeconomic evaluation of antidepressant therapies.
With today's emphasis in the managed care environment on evidentiary literature, new antidepressants must provide economic evidence of their value compared with previously available agents. Various pharmacoeconomic models have shown newer antidepressant agents to be cost-effective relative to older agents. The authors review methodologies and published results.
Applied Health Outcomes, Palm Harbor, FL, USA.
Matthew W
MW
Sarnes
Laura E
LE
Frankum
D000928:Antidepressive Agents / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D008329:Managed Care Programs; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States
D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors